Home›Research›Compare›NAD+ vs Retinalamin
Peptide ComparisonNAD+ vs Retinalamin
Both are Longevity & Cellular peptides.
NAD+
NAD
Half-life: ~1–2 hours (IV); variable (oral)
451 providers listed
Retinalamin
Retinal bioregulator
Half-life: Unknown
1 providers listed
NAD+ carries stronger published evidence (RCT, 4 key studies) than Retinalamin (Review, 2); both are research compounds.
NAD+
Half-life
~1–2 hours (IV); variable (oral)
Retinalamin
Half-life
Unknown
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | NAD+ |
| Oral administration option | NAD+ |
| More provider options (451 vs 1) | NAD+ |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
NAD+
Retinalamin
NAD+
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and…
Mitochondrial quality control in human ageing and longevity.
Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
Retinalamin
Bioavailability and Biological Activities of Food-Derived Di- and Tripeptides: In Silico and In Vitro Studies
Peptide Regulation of Gene Expression and Protein Synthesis in Bronchial Epithelium
About NAD+
NAD+ is a coenzyme central to cellular energy metabolism, serving as an electron carrier in glycolysis, the citric acid cycle, and oxidative phosphorylation. It is also a required substrate for sirtuins (SIRT1–7) and PARP enzymes, which regulate DNA repair, gene expression, and mitochondrial biogenesis. NAD+ levels decline measurably with age; IV or subcutaneous delivery aims to restore intracellular pools more directly than oral precursors such as NMN or NR.
About Retinalamin
Polypeptide bioregulator from bovine retina; normalizes retinal pigment epithelial and photoreceptor cell function; reduces oxidative damage in retinal tissue
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
NAD+
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Retinalamin
No established clinical contraindications
NAD+
Retinalamin
Not enough vendor pricing yet.
Where to source these peptides
NAD+
451 listed
Browse directory →
Providers offeringRetinalamin
1 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Longevity & Cellular Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). NAD+ vs Retinalamin — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/nad-plus/retinalamin